Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan-Reference-Cited by-同舟云学术

Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan

Published:2017-05-03 Issue:5 Volume:12 Page:e0175703
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Wei-Chun,Qiu Jiantai Timothy,Lai Chyong-Huey,Huang Huei-Jean,Lin Cheng-Tao,Chen Min-Yu,Chou Hung-Hsueh,Huang Kuan-Gen,Chang Ting-Chang

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. American Cancer Society. Ovarian cancer. 358 http://www.cancer.org/cancer/359ovariancancer/detailedguide/ovarian-cancer-key-statistics. Accessed March 24, 360 2016

2. Taiwan DoH, Executive Yuan. Cancer Registry Annual Report, 2009. 2011.

3. Tumor angiogenesis: therapeutic implications;J Folkman;N Engl J Med,1971

4. The biology of VEGF and its receptors;N Ferrara;Nat Med,2003

5. VEGF as a therapeutic target in cancer;N Ferrara;Oncology,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer;Frontiers in Oncology;2022-05-19

2. Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results;Cancers;2021-06-26

3. Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience;Frontiers in Oncology;2020-07-14

4. Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors;Journal of Ovarian Research;2018-08-18

5. Bevacizumab;Reactions Weekly;2017-07